Methotrexate and Duobrii drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Methotrexate (methotrexate sodium) and Duobrii (halobetasol propionate; tazarotene). Common drug interactions include headache among females and psoriasis among males.

The phase IV clinical study analyzes what interactions people have when they take Methotrexate and Duobrii. It is created by eHealthMe based on reports of 20 people who take the same drugs from the FDA, and is updated regularly.

What is Methotrexate?

Methotrexate has active ingredients of methotrexate sodium. It is often used in rheumatoid arthritis. eHealthMe is studying from 604,312 Methotrexate users. Check the latest studies of Methotrexate.

What is Duobrii?

Duobrii has active ingredients of halobetasol propionate; tazarotene. eHealthMe is studying from 212 Duobrii users. Check the latest studies of Duobrii.



On Jul, 12, 2026

20 people who take Methotrexate and Duobrii together, and have interactions are studied.

Methotrexate and Duobrii drug interactions.

What are the common drug interactions of Methotrexate and Duobrii, by gender? *:

female:

  1. Headache (pain in head)
  2. Abdominal pain upper
  3. Aggression
  4. Anaphylactic shock (severe and rapid and sometimes fatal hypersensitivity reaction to a substance)
  5. Asthenia (weakness)
  6. Breast swelling
  7. Dehydration (dryness resulting from the removal of water)
  8. Diarrhoea
  9. Disturbance in attention
  10. Drug hypersensitivity

male:

  1. Psoriasis (immune-mediated disease that affects the skin)
  2. Basal cell carcinoma (a skin cancer, it rarely metastasizes or kills)
  3. Skin cancer
  4. Skin fissures (a crack in the skin)
  5. Skin lesion
  6. Vision blurred
  7. Cellulitis (infection under the skin)
  8. Osteomyelitis (infection of bone)
  9. Seborrhoea (a disease of the sebaceous glands characterized by excessive secretion of sebum)
  10. Squamous cell carcinoma (a cancer of a kind of epithelial cell)

What are the common drug interactions of Methotrexate and Duobrii, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

  1. Major depression (a mood state that goes well beyond temporarily feeling sad or blue. it is a serious medical illness that affects one's thoughts, feelings)

50-59:

  1. Abdominal pain upper
  2. Aggression
  3. Anaphylactic shock (severe and rapid and sometimes fatal hypersensitivity reaction to a substance)
  4. Asthenia (weakness)
  5. Breast swelling
  6. Dehydration (dryness resulting from the removal of water)
  7. Diarrhoea
  8. Disturbance in attention
  9. Drug hypersensitivity
  10. Drug ineffective

60+:

  1. Squamous cell carcinoma (a cancer of a kind of epithelial cell)
  2. Psoriasis (immune-mediated disease that affects the skin)
  3. Keratoacanthoma (a common low-grade (unlikely to metastasize or invade) skin tumour that is believed to originate from the neck of the hair follicle)
  4. Lichenoid keratosis (a skin disorder described by rapid growing, reddish to brown, benign (noncancerous) lesion on the skin)
  5. Osteomyelitis (infection of bone)
  6. Seborrhoea (a disease of the sebaceous glands characterized by excessive secretion of sebum)
  7. Surgery
  8. Dyspepsia (indigestion)
  9. Headache (pain in head)
  10. Knee arthroplasty

What are the existing conditions these people have? *

  1. Psoriasis (immune-mediated disease that affects the skin): 7 people, 35.00%
  2. Diabetes: 4 people, 20.00%
  3. Psoriatic Arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop): 3 people, 15.00%
  4. High Blood Pressure: 3 people, 15.00%
  5. Skin Cancer: 2 people, 10.00%
  6. Post Herpetic Neuralgia (neuralgia caused by the varicella zoster virus): 2 people, 10.00%
  7. Gastrointestinal Disorder (functional problems of gastrointestinal tract): 2 people, 10.00%
  8. Chronic Obstructive Pulmonary Disease (a progressive disease that makes it hard to breathe): 2 people, 10.00%
  9. Dermatitis Atopic (inflammatory, chronically relapsing, non-contagious and pruritic skin disorder): 1 person, 5.00%
  10. Arthritis (form of joint disorder that involves inflammation of one or more joints): 1 person, 5.00%

* Approximation only. Some reports may have incomplete information.

Do you take Methotrexate and Duobrii?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Methotrexate and Duobrii:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Methotrexate:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Duobrii:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Methotrexate and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Duobrii and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies


How the study uses the data?

The study uses data from the FDA. It is based on methotrexate sodium and halobetasol propionate; tazarotene (the active ingredients of Methotrexate and Duobrii, respectively), and Methotrexate and Duobrii (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: